logo

For the Inventor, By the Inventor

Halle, Germany

Probiodrug Ag

Calculating rank
USPTO Granted Patents = 73

% Expired Patents = 43.8



Forward Citations = 858

Loading Chart...
Loading Chart...

60 inventors (with patents filed for the assignee):

goldMedal Hans-Ulrich Demuth (53 out of 66 patents)

silverMedal Ulrich Heiser (44 out of 55 patents)

bronzeMedal Stephan Schilling (29 out of 32 patents)

4.  Torsten Hoffmann (20 out of 29 patents)

5.  Mirko Buchholz (19 out of 23 patents)

6.  Andre Johannes Niestroj (17 out of 19 patents)

7.  Jens-Ulrich Rahfeld (16 out of 19 patents)

8.  Daniel Ramsbeck (10 out of 13 patents)

9.  Robert Sommer (8 out of 9 patents)

10.  Holger Cynis (8 out of 10 patents)

11.  Martin Kleinschmidt (7 out of 8 patents)

12.  Michael Thormann (6 out of 17 patents)

13.  Andreas Treml (6 out of 14 patents)

14.  Livia Boehme (6 out of 6 patents)

15.  Sonja Kampfer (5 out of 5 patents)


Core Competencies:
Glutaminyl Cyclase
Humanized Antibodies
Neurodegenerative Diseases
Diagnostic Assay
Amyloid-Beta
Dipeptidyl Peptidase IV
Inflammation Treatment
Mouse Models
Enzyme Inhibitors
Anti-Cancer Agents
Neurological Disorders
Prodrugs

73 patents:

1. 11045533 - Humanized antibodies (2021-06-29),
2. 10603367 - Humanized antibodies (2020-03-31),
3. 9676843 - Uses of antibodies directed against amyloid-β (2017-06-13),
4. 9657089 - Diagnostic antibody assay (2017-05-23),
5. 9656991 - Inhibitors of glutaminyl cyclase (2017-05-23),
6. 9650362 - Inhibitors (2017-05-16),
7. 9610368 - Radiolabelled glutaminyl cyclase (QC) inhibitors and uses of same (2017-04-04),
8. 9512115 - Inhibitors (2016-12-06),
9. 9512082 - Inhibitors of glutaminyl cyclase (2016-12-06),
10. 9462793 - Mouse carrying a knock-out mutation of the Qpct-gene (2016-10-11),
11. 9277737 - Mouse models carrying a knock-out mutation of the QPCTL-gene (2016-03-08),
12. 9181233 - Inhibitors of glutaminyl cyclase (2015-11-10),
13. 9173885 - Inhibitors (2015-11-03),
14. 9157918 - Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (MCP-1 N1pE) (2015-10-13),
15. 9156907 - Diagnostic antibody assay (2015-10-13),
Company Overview
Probiodrug AG, based in Halle, Germany, specializes in the development of innovative therapeutics targeting neurodegenerative diseases. The company focuses on glutaminyl cyclase inhibitors, which play a crucial role in modulating amyloid-beta levels, a key factor in Alzheimer's disease pathology. In addition to its core technology in glutaminyl cyclase, Probiodrug is advancing humanized antibodies and diagnostic assays, contributing to the understanding and treatment of inflammation and related conditions through sophisticated mouse models.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

73 Patents

#1 in Halle

#788 in Germany

#10,271 in the World

Halle, DE
Halle, Germany

Probiodrug Ag

Forward Citations = 858

60 inventors:

goldMedal Hans-Ulrich Demuth (53 out of 66 patents)

silverMedal Ulrich Heiser (44 out of 55 patents)

bronzeMedal Stephan Schilling (29 out of 32 patents)

4.  Torsten Hoffmann (20 out of 29 patents)

5.  Mirko Buchholz (19 out of 23 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Probiodrug Ag. Retrieved from https://idiyas.com/company/probiodrug-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…